Findings

What do systematic reviews say?

2 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 0 · 0%Moderate 1 · 25%High 1 · 25%

Docetaxel vs non‐docetaxel‐containing regimens

Progression‐free survival · people with advanced gastric cancer

Docetaxel probably leads to lower progression‐free survival compared with non‐docetaxel‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.76 [0.63, 0.91]
5 studies · 1498 participants
Moderate

Docetaxel vs non‐docetaxel‐containing regimens

Progression‐free survival (PSF) · people with advanced gastric cancer

It is very uncertain whether docetaxel changes progression‐free survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (very low certainty).

3 findings from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 1.15 [0.77, 1.72]
1 study · 119 participants
Very low
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.7 [0.61, 0.81]
3 studies · 1323 participants
High
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.94 [0.55, 1.6]
1 study · 56 participants
Very low